The company reported the Phase III DIVERSITY trial of Jyseleca did not meet its primary endpoint in Crohn’s disease, closing another path to the US market.

After scoring a long-term multi-billion dollar deal with Gilead, Galapagos rushed into clinical trials and paid the price. Paul Stoffels talks to Scrip about returning to his Belgian roots and turning around the company he co-founded.

As the usual flurry of deals coincides with the J.P. Morgan Healthcare Conference, AbbVie signed an mRNA pact with Anima and a cancer research tie-up with Immunome.

Daily notebook from the J.P. Morgan Healthcare Conference: Small and mid-size companies take the stage to lay out their guidance for the year, while big pharma is pushed on strategy and business development. Updates from GSK, Mirati, Sarepta, Amgen and US FDA commissioner Robert Califf.